Are we making the right choices to bring new drugs to the marketplace?
This is a preview of subscription content, log in via an institution to check access.
References
Projan, S. J. Curr. Opin. Microbiol. 6, 427–430 (2003).
Wenzel, R. P. N. Engl. J. Med. 351, 523–526 (2004).
Infectious Diseases Society of America. Bad Bugs, No Drugs; http://www.idsociety.org/Template.cfm?Section=Home&CONTENTID=7455&TEMPLATE=/ContentManagement/ContentDisplay.cfm (2004).
Centers for Disease Control and Prevention. A Public Health Action Plan to Combat Antimicrobial Resistance; http://www.cdc.gov/drugresistance/actionplan/html/index.htm (2000).
Coates, A., Hu, Y., Bax, R. & Page, C. Nature Rev. Drug Discov. 1, 895–910 (2002).
World Health Organization Draft Global Strategy for the Containment of Antimicrobial Resistance; http://www.who.int/emc/amr.html (2001).
Service, R. F. Science 303, 1796–1799 (2004).
Walsh, C. Nature Rev. Microbiol. 1, 65–70 (2003).
Miesel, L., Greene, J. & Black, T. A. Nature Rev. Genet. 4, 442–456 (2003).
Global Alliance for Tuberculosis Drug Development. The Economics of TB Drug Development; http://www.tballiance.org/pdf/Economics%20Report%20Full%20(final).pdf (2001).
Chopra, I., Hodgson, J., Metcalf, B. & Poste, G. J. Am. Med. Assoc. 275, 401–403 (1996).
Darwin, K. H., Ehrt, S., Gutierrez-Ramos, J. C., Weich, N. & Nathan, C. F. Science 302, 1963–1966 (2003).
Bryk, R., Lima, C. D., Erdjument-Bromage, H., Tempst, P. & Nathan, C. Science 295, 1073–1077 (2002).
Schnappinger, D. et al. J. Exp. Med. 198, 693–704 (2003).
Sassetti, C. M., Boyd, D. H. & Rubin, E. J. Mol. Microbiol. 48, 77–84 (2003).
Tong, A. H. et al. Science 303, 808–813 (2004).
Fidock, D. A., Rosenthal, P. J., Croft, S. L., Brun, R. & Nwaka, S. Nature Rev. Drug Discov. 3, 509–520 (2004).
Manetsch, R. et al. J. Amer. Chem. Soc. 126, 12809–12819(2004).
Keller, M. & Zengler, K. Nature Rev. Microbiol. 2, 141–150 (2004).
Liu, J. et al. Nature Biotechnol. 22, 185–191 (2004).
Nwaka, S. & Ridley, R. G. Nature Rev. Drug Discov. 2, 919–928 (2003).
Vennerstrom, J. L. et al. Nature 430, 900–904 (2004).
World Health Organization, Commisssion on Macroeconomics and Health Macroeconomics and Health: Investing in Health for Economic Development; http://www.cmhealth.org (2001).
Acknowledgements
Thanks to A. Apt, K. Deitsch, H. Djaballah, B. Ganem, W. Jorgensen, T. Kapoor, M. MacCoss, V. Mizrahi, S. Projan, L. Quadri, K. Rhee, M. Rosenberg, D. Russell, D. Scheinberg, D. Schnappinger, D. Tan, T. Templeton and P. van Helden for stimulating discussions. Special thanks are due to P. Davies, S. Ehrt, M. Glickman, B. Kelly, J. McKinney and S. Nwaka.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nathan, C. Antibiotics at the crossroads. Nature 431, 899–902 (2004). https://doi.org/10.1038/431899a
Published:
Issue Date:
DOI: https://doi.org/10.1038/431899a
- Springer Nature Limited
This article is cited by
-
Nanomaterials arising amid antibiotic resistance
Nature Reviews Microbiology (2021)
-
DFT calculation, molecular docking, and molecular dynamics simulation study on substituted phenylacetamide and benzohydrazide derivatives
Journal of Molecular Modeling (2021)
-
Antibiotic effect and microbiome persistence vary along the European seabass gut
Scientific Reports (2020)
-
Modification and de novo design of non-ribosomal peptide synthetases using specific assembly points within condensation domains
Nature Chemistry (2019)
-
Characterization and safety evaluation of partially purified bacteriocin produced by Escherichia coli E isolated from fermented pineapple Ananas comosus (L.) Merr
Brazilian Journal of Microbiology (2019)